Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier

Fig. 5

PARP inhibition prevents conformational activation of VLA-4 (integrin β1) in monocytes. Monocytes were treated with PARPi (AIQ or EB47) or RhoA or Rac1 GTPase inhibitor (CT04 or NSC23766). The expression of total VLA-4 (CD29) was unaffected by treatment with PARP inhibitors. a The active form of VLA-4 was detected using HUTS21, a conformation-specific antibody. Integrin conformation in monocytes changes from a closed (inactive) to an open (active) form after LDV stimulation. Total amount of integrin β1 (CD29) is shown on the x-axis. b Quantitation of integrin β1 conformational activation, expressed as the percent of monocytes containing the activated integrin conformation (as shown in the right upper quadrant of each graph in panel a). Results are presented as the mean ± SEM (**P < 0.01, ****P < 0.005 vs. untreated control) from three independent experiments

Back to article page